Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Explore use cases
for our technology
N-Force toolbox
A powerful toolbox of technologies, to fast track your RNA development from design to delivery
Our toolbox of technologies provides our partners with a comprehensive set of solutions to enable RNA adoption, starting from a simple antigen sequence. It provides solution for molecular design, RNA production and formulation as well as support in derisking studies in-vitro and in-vivo.
RNA design
Bioinformatics platform
RNA production
Through redesigned and optimized (sa)mRNA process
for Drug Product RNA-LNP
RNA design
Bioinformatics platform
RNA design platform, from amino acid sequence to optimally functional RNA
RNA production
through redesigned and optimized (sa)mRNA process
A (sa)mRNA production platform that is construct agnostic. It includes a process, mixes of reagents, disposables and scalable equipment from R&D to large scale commercial production
RNA delivery
through new delivery chemistry and optimized process
Formulation equipment for GMP applications
Proprietary chemistries for LNP production
Management Team
Click on each picture to see the bio of each member
Jose Castillo
Chief Executive Officer
(& Univercells co-founder)
Jose Castillo
Chief Executive Officer
(& Univercells co-founder)
José Castillo co-founded Univercells in 2013 and still serves as the company’s Chief Technology Officer today. Under his leadership, Univercells has become a pioneering force in the biopharmaceutical industry, with highly efficient production processes that aim to make biologics available and affordable for all. His goal was to disrupt the industry and position Univercells as a leader in comprehensive manufacturing solutions.
In June 2021, building on his success at Univercells, José launched Quantoom Biosciences, a cutting-edge biotech with a mission to remove the barriers to making mRNA-based vaccines and therapeutics, from sequence up to mass production. As the CEO of Quantoom Biosciences, José continues to drive innovation and create solutions that have the potential to revolutionize mRNA production.
As a recognized technology leader in the biopharmaceutical industry, José brings a strong track record in innovative process design and successful commercialization. Previous accomplishments include the start-up of Artelis, where he designed and developed bioreactors that transformed industrial operations – the iCellis system is now considered standard in the vaccines and gene therapy industry. The technology was industrialized at ATMI LifeSciences and Pall Lifesciences, where José held the position of Cell Culture Technologies Director. Before Artelis, José was Head of Viral Vaccine Industrialization at GSK Vaccines.
With a background in Chemical Engineering, Jose’s education includes a PhD in Applied Sciences from the Université Libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.
Guillaume Roelandts
Head of Products, Marketing & Sales
Guillaume Roelandts
Guillaume leads the company’s commercial strategy definition and execution, overseeing the development & management of the product portfolio, strategic marketing activities, technologies’ market adoption & sales on a global scale, as well as corporate branding & communications.
He joined José Castillo in 2020 when the project was in its incubation phase within Univercells and has since supported the development of Quantoom Biosciences by combining his experience in business strategy and commercial excellence with his passion for innovation in the life sciences sector. Prior to joining Quantoom Biosciences, he initially worked in innovation management roles in the industry and then joined the strategy consulting firm Strategy& (formerly Booz & Company), covering various sectors including industry, transport, retail, and private equity & venture capital.
Guillaume graduated from Solvay Business School (ULB) in Belgium with an MSc in Business Engineering, supplemented by a program in Corporate Finance at HEC Paris Executive Education.
Coralie Pirlot
Financial Director
Coralie Pirlot
Financial Director
With over a decade of multifaceted experience across various industries, roles and countries, Coralie is a finance professional adept at navigating complex business landscapes. Currently serving as the Finance Director at Univercells, overseeing the financial operations of Quantoom Technologies and Univercells R&D divisions, Coralie brings a wealth of expertise in financial management and strategic planning in various sectors.
Prior to this role, Coralie served as the Group FP&A Manager at Atalian, a prominent figure in the facility management industry. Leading a team of FP&A analysts, Coralie played a pivotal role in driving corporate financial performance analysis, budgeting, forecasting, and procurement controlling, demonstrating a keen ability to align financial strategies with organizational objectives.
With previous experience in the pharmaceutical industry at Galapagos as a Senior Project Lead, Coralie was instrumental in developing commercial controlling processes and providing financial support for operational and strategic decision-making. This role showcased Coralie’s proficiency in financial excellence, business partnering, and process optimization, contributing to the company’s success in a highly competitive market.
Before transitioning into the biotech sector, Coralie honed her skills in the legal industry, serving as the Manager of Business Operations at Morgan Lewis & Bockius LLP, in the USA as well as the UK. Spearheading business operations activities across EMEA and Asia Pacific regions, Coralie played a key role in financial planning, reporting, pricing strategies, and client billing rate management, earning recognition for her contributions to the firm’s operational efficiency and client satisfaction.
Coralie began her career in banking at ING Belgium, where she held roles in corporate sales and associate relationship management. Responsible for advising large corporations on financial risk hedging and executing financial market products, Coralie developed a reputation for excellence in client relationship management, complex financial analysis, and regulatory compliance.
Throughout Coralie’s career journey, she has consistently demonstrated a commitment to excellence, adaptability in diverse environments, and a passion for driving results. Armed with a robust skill set and a track record of success, Coralie is poised to continue making impactful contributions in Quantoom and Univercells.
Strategic & scientific
advisory board
Pierre Morgon
Board Member
Jean-Paul Prieels
Board Member
Michel De Wilde
Andrin Oswald
Beate Kampmann
Our partners
Driving innovation through strategic collaborations
Since its incorporation, Quantoom Biosciences has built strong partnerships with key international organizations and strategic institutions in order to develop truly affordable and accessible production technologies.
In June 2021, Quantoom Biosciences entered into a strategic collaboration with eTheRNA immunotherapies to develop a revolutionary RNA Production System (RPS) aimed at making RNA therapeutics more accessible and affordable globally. By combining their expertise, Quantoom and eTheRNA would pave the way for the widespread availability of essential RNA medicines, transforming the future of personalized healthcare.
The Afrigen partnership paves the way for the development of the first-ever African-owned COVID-19 vaccine. Afrigen hosts the World Health Organization’s Global mRNA Vaccine Technology Transfer Hub and is working to facilitate the production of mRNA vaccines at over 15 designated manufacturing sites in LMICs across the world. The collaboration focuses on development of a novel mRNA vaccine using intellectual property from the collaboration partners, as well as developing new IP, to supercharge access to the vaccine.
In early 2023, Quantoom Biosciences entered into a public-private partnership with Immunewatch and the University of Antwerp. The collaboration aims to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process.
The proposed methodology is expected to significantly reduce both time and costs in the preclinical development of vaccines. To demonstrate its potential, the team has selected a rabies vaccine candidate as a proof-of-concept.
The Biotechnology and Biological Sciences Research Council (BBSRC), the Foreign, Commonwealth and Development Office (FCDO), and the Bill & Melinda Gates Foundation have collectively invested nearly £40 million to support a ‘one health’ approach to improving the health and wellbeing of animals and humans globally. The newly established Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) will serve as a bridge, connecting research with expertise in process development and manufacturing.
The NucNanoFish project, led by ICRAD, has brought together a consortium of six partners with highly complementary expertise to develop new vaccines aimed at preventing viral diseases in fish to promote sustainable aquaculture. The consortium includes a company specializing in the nanodelivery of antigens and mRNA using lipid nanoparticles (LNP), four groups of fish immunovirologists and vaccinologists, and Quantoom Biosciences who will focus on DNA production.